Dr med vet Andrea Kelly is a medical specialist for microbiology, clinical project manager and Principal Clinical research associate at the Division of Infectious Diseases and Tropical Medicine of the LMU Munich. Andrea is part oft he development team managing phase II studies on Sutezolid and Delpazolid
Consecutive to 5 years as a postdocteral fellow in the TUM Institute for Molecular Virology Andrea has been working for almost 20 years in clinical development with PPD. As a principal CRA she was responsible for site management on clinical trials phase II and III for various indications, cancer research, ophtalmology, neurology and autoimmune diseases during start up, maintenance and close out in the DACH region. During that time Andrea attended several audits and inspection by German and Austrian authorities
Johann de Bruyn is the Chief Executive Officer of TASK, a multi-site clinical research institute based in Cape Town, South Africa. He specialises in growth strategies and change management in organisations, and have successfully managed teams across various industries.
In 2015 Hamza completed his studies in Accounting at the HAN University in Nijmegen. In 2016 he started working at Konings & Meeuwissen as assistant accountant working mainly for regional clients. At the same time he started his study Post Bachelor AA Accounting at the HAN University in Arnhem. In 2019 he started working for GX Software as Finance Professional. He managed all the finances and did the payroll for the organisation. In 2022 he started working for Radboudumc as Financial manager for PanACEA II besides Rutger Spoor. Focussing on budgeting, financial reporting and auditing the financial reports from partners.
Bayode Romeo ADEGBITE is a medical doctor, and researcher at Centre de Recherches Médicales de Lamabaréné (CERMEL), Gabon and partner institution Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Center
Dr. ADEGBITE has been a medical doctor and public health expert for Benin republic ministry of Health and the Global Fund. He has joined CERMEL as medical researcher. Currently He is leading the TB research program, implementing observational studies and clinical trials in TB therapeutics and diagnostics in adult and paediatric population at CERMEL. Dr. ADEGBITE is currently the Principal Investigator in several infectious disease studies, including clinical trials for new drugs. His main research interest includes tuberculosis, sepsis, antimicrobial resistance and tropical diseases.
Caryn Upton is a medical doctor with 5 years’ experience as an investigator in clinical trials at TASK focused on infectious diseases such as TB and COVID-19. She has a special interest in underserviced populations with TB such as those with TB meningitis and is a PhD candidate through Radboud University looking into the CSF penetration of established and novel TB drugs into the CSF. Dr Upton is principal investigator of a few clinical trials, two of which are focused on novel regimens and treatment shortening in patients with drug-resistant TB, and recently a study on BCG (re)vaccination to reduce morbidity due to COVID-19. She is currently the Scientific Officer for TASK and also assists in grant management and collaborations with global sponsors.
Lisa Espig studied health sciences at the Technical University of Munich for her bachelor’s and master’s degrees. Her areas of focus were scientific research methods and ethics. During those years, she gained first practical experience in the field of clinical research by supporting several university hospitals. She worked in the data management of clinical trials and directly in patient contact by collecting neurophysiological data from patients. After her studies, she worked for a global clinical contract research organization (CRO) as a regulatory submissions coordinator. She was responsible for submissions to the regulatory authorities (e.g., PEI, BfArm) and ethics committees. In July 2021, Lisa joined the Division of Infectious Diseases and Tropical Medicine at the LMU Munich as a junior clinical project manager for PanACEA TB trials and other projects in Africa.
Dr. rer. nat. Petra Gross-Demel is a scientist and clinical project manager at the Division of Infectious Diseases and Tropical Medicine of the LMU Munich. Petra is part of the development team managing phase II studies of the new investigational antibiotic BTZ-043 for tuberculosis.
Petra has been working for more than 20 years in clinical development at Sandoz/Novartis and in a CRO. As a globally acting Clinical Research Manager she managed phase I and III studies and developed global clinical program designs of superiority- pharmacokinetic-, bioequivalence-, non-inferiority, equivalence-studies including compilation or review of clinical and bioanalytical protocols, ICF, CRF, validation and bioanalytical reports under consideration of drug metabolism.
Dr. Francis Mhimbira is an epidemiologist and a senior research scientist at Ifakara Health Institute (IHI, www.ihi.or.tz). He joined IHI since 2012 working with a TB research group conducting TB epidemiological, diagnostic and clinical trials (drugs and vaccines). He has experience in conducting phase II and phase III TB drug clinical trials. He is currently leading the preparation and conduct of PanACEA related studies at Ifakara Health Institute. Dr. Francis has other research interests which include implementation studies on TB case finding and diagnostic studies.
Dr. Francis received his medical degree from University of Dar es Salaam, Tanzania, a Masters’ degree in Epidemiology from University of Melbourne, Australia and a PhD in Epidemiology from University of Basel, Switzerland.
Celso Khosa is the scientific director of Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), Instituto Nacional de Saúde Mozambique (INS) since 2018 and he is responsible for the daily activities of PanACEA II in Mozambique.
Dr. Khosa has been a medical doctor and researcher at INS-CISPOC since 2013, leading the TB research program, implementing observational studies and clinical trials in TB therapeutics and diagnostics in adult and paediatric population. He is a last year PhD candidate in Medical Research / International Health at the University of Munich. Dr. Khosa is currently the Principal Investigator in several TB studies, including clinical trials for new drugs in TB and HIV treatment.
His main research interest includes tuberculosis, HIV and Comorbidities associated with HIV.
Dr. Julia Dreisbach, a veterinary doctor, led the preclinical development of BTZ-043 and now acts as clinical project manager in the BTZ-043 Multiple Ascending Dose Study in Patients.
She coordinates in parallel all non-clinical activities like for example long term toxicity studies in animals, cold- and radiolabeled ADME studies in animals and the development of a suitable drug formulation for BTZ-043